Apnimed
Ramzi Benamar currently serves as the Chief Financial Officer at Apnimed since October 2024. Prior to this role, Benamar held the position of Chief Financial Officer at Elucida Oncology, Inc. from August 2023 to June 2024 and at Bellus Health from December 2020 until its acquisition by GSK in July 2023. Additional experience includes serving as Chief Financial Officer at DBV Technologies in early 2020 and as Head/Vice President of Financial Planning & Analysis and Finance Business Partnering at Spark Therapeutics, Inc. from January 2017 to January 2020, prior to its acquisition by Roche Holding AG. Ramzi Benamar holds both a Bachelor and Master of Business Administration from Temple University and a Master’s degree from the University of the Sciences in Philadelphia.
This person is not in any teams
This person is not in any offices
Apnimed
Apnimed is a clinical-stage company dedicated to the discovery of novel pharmacologic therapies for sleep apnea and related disorders.Sleep apnea is a common, serious condition with significant morbidity, increased mortality, and substantial effects on daily functioning. Sleep apnea affects more than 20 million Americans and has seriousconsequences. OSA is caused by a combination of predisposing anatomical factors and sleep-related decrements of activity in upper airway muscles.Current treatments primarily rely on positive pressure devices, e.g., CPAP, to maintain airway patency. Less commonly used treatments include mandibular advancement devices, nerve stimulation, and surgical interventions.Apnimed was founded in 2017 and is located in Cambridge, Massachusetts.